Ehrenkranz Rebecca, Agrawal Manish, Nayak Sandeep M, Yaden David B
Center for Psychedelic and Conciousness Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sunstone Therapies, Rockville, Maryland, USA.
Psychedelic Med (New Rochelle). 2025 Feb 27;3(1):59-62. doi: 10.1089/psymed.2024.0006. eCollection 2025 Mar.
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics within the scientific community and broader public. Coverage of psychedelic science has swung between a pendulum of extremes, from fearmongering in past decades to effusive optimism today. Public discourse about the risks and benefits of psychedelics can and should instead be grounded in the growing evidence from clinical trials as well as participant reports. While most adverse events related to pyschedelics are mild, some have been severe and serious, and public education about the existence and nature of those risks is necessary. We predict that as more studies are conducted and eligibility criteria are relaxed to improve access, the incidence and severity of adverse events will increase. While no medical intervention is risk-free, it will be increasingly important to quantify and effectively communicate the risk/benefit profile of psychedelics.
研究表明，将迷幻药用作多种心理健康状况的治疗干预措施既有风险也有好处。近年来，围绕迷幻药治疗的公众讨论在很大程度上是积极的，且更多地关注好处而非风险。我们认为，科学界和更广泛的公众对迷幻药的风险和好处给予更平衡的关注将使该领域受益。迷幻药科学的报道在两个极端之间摇摆不定，从过去几十年的危言耸听到如今的过度乐观。关于迷幻药风险和好处的公众讨论可以而且应该基于来自临床试验以及参与者报告的越来越多的证据。虽然与迷幻药相关的大多数不良事件是轻微的，但有些是严重的，对这些风险的存在和性质进行公众教育是必要的。我们预测，随着进行更多的研究并放宽资格标准以改善可及性，不良事件的发生率和严重程度将会增加。虽然没有任何医疗干预是没有风险的，但量化并有效传达迷幻药的风险/益处概况将变得越来越重要。
